Journal Article

In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.

Itamar Shalit, Yona Shadkchan, Gabriel Mircus and Nir Osherov

in Medical Mycology

Published on behalf of International Society for Human and Animal Mycology

Volume 47, issue 5, pages 457-462
Published in print August 2009 | ISSN: 1369-3786
Published online August 2009 | e-ISSN: 1460-2709 | DOI: https://dx.doi.org/10.1080/13693780802232910
In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.

More Like This

Show all results sharing these subjects:

  • Mycology and Fungi
  • Infectious Diseases
  • Medical Toxicology
  • Veterinary Medicine
  • Environmental Science

GO

Show Summary Details

Preview

Combinations of caspofungin (CAS) with amphotericin-B (AMB), voriconazole (VRC), terbinafine (TRB) and tacrolimus (FK-506) were tested in vitro with 10 Fusarium isolates. MIC and minimal effective concentrations (MEC) were investigated in accord with the CLSI methodology. Drug interactions were assessed by the fractional inhibitory concentration index (FICI). Synergy occurred in 10/10, 9/10, 7/10 and 4/10 isolates with CAS/FK-506, CAS/TRB, CAS/AMB and CAS/VRC, respectively. Caspofungin MECs reached clinically attainable concentrations with FK-506 and TRB. Hyphal length and DiBAC staining demonstrated enhanced inhibition and killing with CAS/FK-506 and CAS/TRB. The combination of CAS/TRB and CAS/FK-506 is strongly synergistic in vitro against Fusarium spp. Our finding should be further studied in animal models of invasive infections caused by this fungus.

Keywords: Caspofungin; Fusarium; synergy; tacrolimus; terbinafine

Journal Article.  1913 words.  Illustrated.

Subjects: Mycology and Fungi ; Infectious Diseases ; Medical Toxicology ; Veterinary Medicine ; Environmental Science

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.